Clinical trials: Alzheimer Disease 1
AL Amyloidosis
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Light chain (AL) amyloidosis is a bone marrow disorder that affects a wide range of organs that can lead to organ dysfunction and death.
- Trial name
- NCT03236792
- Testing
- Ixazomib, Cyclophosphamide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
This is a two-part multiple dose study in healthy male and female (of non-child bearing potential) elderly volunteers, and in Alzheimer's disease patients, to assess the safety, effects on the body, and blood, CSF, and urine drug…
- Trial name
- NCT01795339
- Testing
- AZD3293
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer Disease
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
- Trial name
- NCT06511570
- Testing
- sabirnetug (ACU193), Sabirnetug + rHuPH20
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Acumen Pharmaceuticals
Alzheimer Disease (AD)
Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease
The study aims to compare tau targeted radiotracers [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).
- Trial name
- NCT04566003
- Testing
- [18F]GTP1, [18F]PI-2620, [18F]MK-6240
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
Parkinson's Disease, Dementia
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases.
- Conditions
- Parkinson's Disease, Dementia, Alzheimer's Disease, ALS
- Trial name
- NCT04396873
- Testing
- 11C-MC1, 11C-PS13, 18f-florbetaben
- Where
- United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Dementia, Alzheimer Disease 1
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.
- Conditions
- Dementia, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT03806478
- Testing
- APH-1105
- Volunteers
- 60 people
- Sponsor
- Aphios
Alzheimer Disease, Dementia Alzheimer Type
Cervical Lymphatico-Venous Bypass for Treatment of Alzheimer's Disease - Proof of Concept Study (CLyVeB-AD-1 Study)
Alzheimer's disease (AD), one of the most common causes of dementia in Singapore and the developed world, is a neurodegenerative disorder with high socioeconomic impact. Accumulation of neurotoxic proteins (ie.
- Conditions
- Alzheimer Disease, Dementia Alzheimer Type, Dementia Alzheimer's Type, Alzheimer's Disease
- Trial name
- CLyVeB-AD-1 (NCT06965062)
- Testing
- Deep cervical lymph node to venous bypass (DCLNV-BP)
- Where
- Singapore
- Volunteers
- 10 people
- Sponsor
- Vincent Tay Khwee Soon
H5N1 Influenza
Experimental AD4-H5-VTN Vaccine in Healthy Volunteers
This is a Phase 1 randomized, single center, dose-escalation study designed to evaluate the safety and immunogenicity of live, replication competent recombinant Adenovirus type 4-H5N1Influenza Vietnam 1194 Hemagglutinin (HA)…
- Trial name
- NCT01443936
- Testing
- Ad4-H5-VTN vaccination-tonsillar route, Ad4-H5-vaccination-oral route
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)
This phase III clinical trial is an endpoint-driven randomized, double-blind, parallel-controlled, multicenter clinical trial, and around 13,000 subjects aged 18 years and above who have previously received 1 dose of…
- Trial name
- NCT05124561
- Testing
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
- Volunteers
- healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Mild Cognitive Impairment, Alzheimer Disease
Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease participants.
- Trial name
- Allo (NCT02221622)
- Testing
- Allopregnanolone injection (intravenous solution)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Southern California
Alzheimer's Disease, Mild Cognitive Impairment
A Light Exposure Tracker Designed to Improve Circadian Rhythms - Aim 1
The purpose of this research study is to investigate the relationship between reminder messages sent via text and compliance with a daily morning light intervention designed to advance the circadian clock.
- Trial name
- NCT06356337
- Testing
- Light goggles, Daily reminder test message
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer's Disease
A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of the study is to evaluate the safety of PF-04447943 when given in combination with donepezil in subjects who have Alzheimer's Disease.
- Trial name
- NCT00988598
- Testing
- PF-04447943
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
The purpose of the study is to examine the safety, tolerability, immunogenicity and pharmacokinetics of TTP4000 in subjects with Alzheimer's disease with mild cognitive impairment.
- Trial name
- NCT01548430
- Testing
- TTP4000
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- vTv Therapeutics
Cognitive Function 1, Social
Evaluating Cognitive and Functional Impairment in Alzheimer's Dementia With a Ketogenic Diet.
The present study is being done in a scientifically rigorous manner, using readily available MCT oil (refined from coconut oil) versus a placebo oil to assess any cognitive and functional benefits for AD patients.
- Trial name
- NCT04396015
- Testing
- Bulletproof Brain Octane
- Volunteers
- 20 people
- Sponsor
- University of Alberta
Alzheimer's Disease
A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)
A study to assess the effect of heat application on the delivery profile of Corplex™ Donepezil Transdermal Delivery System (TDS)
- Trial name
- NCT03438604
- Testing
- Donepezil TDS
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Corium, Inc.
Alzheimer's Disease, Mild Cognitive Impairment
System-IGF-1 Pathway and Alzheimer's Disease
The aim is to assess the relationship between levels of IGF-I system components and cognitive status in patients with Alzheimer's disease (AD), in elderly subjects with normal cognitive function, and in patients with mild…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Cognitive Function 1, Social, Control With Normal Activities of Daily Living
- Trial name
- SIGAL (NCT00647478)
- Where
- France
- Volunteers
- 693 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer Disease
A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants
This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of intravenously (IV) or subcutaneously (SC) injected…
- Trial name
- NCT06406348
- Testing
- ALIA-1758
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- AbbVie
Alzheimer Disease
Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production
This is a Phase I, single center, open label, multiple dose, pharmacokinetic (PK) study recruiting healthy older subjects.
- Trial name
- NCT04268953
- Testing
- Tricaprilin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cerecin
Alzheimer Disease
Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers
This an open label study to assess the pharmacokinetics of CT1812 in normal healthy volunteers.
- Trial name
- COG0107 (NCT05248672)
- Testing
- CT1812
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Cognition Therapeutics
HIV
Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.
The goal of this clinical trial is to test 16055 NFL delta Gly4 Env protein trimer and Trimer 4571 combined with 3M-052-AF + Alum adjuvant and Ad4-Env145NFL viral particles as heterologous prime-boost regimens in adult…
- Trial name
- NCT06332339
- Testing
- 16055 NFL delta Gly4 trimer, Trimer 4571, Ad4-Env145NFL, 5 x 108 viral particles (vp)
- Where
- 6 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)